Chimerix, Inc. (CMRX) Cut to “Hold” at Zacks Investment Research
According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “
Separately, FBR & Co reiterated a hold rating and issued a $8.00 price objective on shares of Chimerix in a research note on Wednesday, January 11th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. Chimerix presently has an average rating of Hold and a consensus price target of $7.70.
Chimerix (NASDAQ:CMRX) traded up 0.17% during mid-day trading on Thursday, hitting $5.98. 137,620 shares of the stock traded hands. Chimerix has a 12-month low of $3.49 and a 12-month high of $7.84. The firm’s 50-day moving average is $5.18 and its 200-day moving average is $4.88. The company’s market cap is $276.96 million.
This news story was originally reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright and trademark law. The legal version of this news story can be viewed at http://www.watchlistnews.com/chimerix-inc-cmrx-cut-to-hold-at-zacks-investment-research/1120772.html.
In other Chimerix news, Director Ernest Mario sold 100,000 shares of Chimerix stock in a transaction dated Wednesday, December 28th. The shares were sold at an average price of $4.64, for a total transaction of $464,000.00. Following the completion of the transaction, the director now owns 12,905 shares in the company, valued at $59,879.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.50% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Redmile Group LLC acquired a new position in shares of Chimerix during the second quarter worth about $12,923,000. Numeric Investors LLC boosted its position in shares of Chimerix by 54.6% in the second quarter. Numeric Investors LLC now owns 2,073,774 shares of the biopharmaceutical company’s stock worth $8,150,000 after buying an additional 732,604 shares during the last quarter. EcoR1 Capital LLC boosted its position in shares of Chimerix by 136.7% in the fourth quarter. EcoR1 Capital LLC now owns 1,415,687 shares of the biopharmaceutical company’s stock worth $6,512,000 after buying an additional 817,625 shares during the last quarter. Arrowpoint Asset Management LLC boosted its position in shares of Chimerix by 27.2% in the fourth quarter. Arrowpoint Asset Management LLC now owns 1,045,517 shares of the biopharmaceutical company’s stock worth $4,809,000 after buying an additional 223,495 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Chimerix by 2.6% in the fourth quarter. State Street Corp now owns 751,031 shares of the biopharmaceutical company’s stock worth $3,453,000 after buying an additional 18,688 shares during the last quarter. Institutional investors own 68.66% of the company’s stock.
Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.